Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Antibe Therapeutics Inc. (ATBPF : OTC)
 
 • Company Description   
Antibe Therapeutics Inc. is a biotech company with a drug platform of therapeutics in pain and inflammation. Its lead drug candidate consists of ATB-346, non-addictive drug for chronic pain and inflammation; ATB-352, for a non-addictive analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin. Antibe Therapeutics Inc. is based in Toronto, Canada.

Number of Employees: 37

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.53 Daily Weekly Monthly
20 Day Moving Average: 4,534 shares
Shares Outstanding: 52.10 (millions)
Market Capitalization: $27.83 (millions)
Beta: 0.29
52 Week High: $3.57
52 Week Low: $0.48
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -9.24% 2.21%
12 Week -4.78% 4.68%
Year To Date 3.55% 30.26%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
15 PRINCE ARTHUR AVENUE
-
TORONTO,A6 M5R 1B2
CAN
ph: 416-922-3460
fax: -
christina@antibethera.com http://www.antibethera.com
 
 • General Corporate Information   
Officers
Dan Legault - Chief Executive Officer & Director
Walt Macnee - Chairman
Alain Wilson - Chief Financial Officer
Roderick Flower - Director
Robert Hoffman - Director

Peer Information
Antibe Therapeutics Inc. (CORR.)
Antibe Therapeutics Inc. (RSPI)
Antibe Therapeutics Inc. (CGXP)
Antibe Therapeutics Inc. (BGEN)
Antibe Therapeutics Inc. (GTBP)
Antibe Therapeutics Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 037025509
SIC: 2834
Fiscal Year
Fiscal Year End: March
Last Reported Quarter: 12/01/21
Next Expected EPS Date: 06/27/22
Share - Related Items
Shares Outstanding: 52.10
Most Recent Split Date: 12.00 (0.10:1)
Beta: 0.29
Market Capitalization: $27.83 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.39 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 06/27/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.57
Price/Cash Flow: -
Price / Sales: 3.13
EPS Growth
vs. Year Ago Period: 33.33%
vs. Previous Quarter: 38.46%
Sales Growth
vs. Year Ago Period: 1.77%
vs. Previous Quarter: -1.44%
ROE
03/31/22 - -
12/31/21 - -42.02
09/30/21 - -52.35
ROA
03/31/22 - -
12/31/21 - -27.96
09/30/21 - -34.99
Current Ratio
03/31/22 - -
12/31/21 - 17.91
09/30/21 - 19.00
Quick Ratio
03/31/22 - -
12/31/21 - 17.91
09/30/21 - 19.00
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -237.01
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -244.59
Pre-Tax Margin
03/31/22 - -
12/31/21 - -305.83
09/30/21 - -236.67
Book Value
03/31/22 - -
12/31/21 - 0.94
09/30/21 - 0.99
Inventory Turnover
03/31/22 - -
12/31/21 - 3.12
09/30/21 - 3.06
Debt-to-Equity
03/31/22 - -
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - -
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©